Diabetes CV Outcomes Trials Generate New Questions For FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee will discuss imbalances in heart failure hospitalization and all-cause mortality with AstraZeneca’s saxagliptin and subgroup differences for Takeda’s alogliptin. Even though the DPP-4 inhibitors had neutral effects overall on major adverse CV events, FDA still sees utility in long-term safety studies.
You may also be interested in...
Will CV Verdicts For Onglyza, Nesina Cause FDA To Change Its Tune On Antidiabetic Safety?
Large outcomes studies showed neither cardiovascular harm nor benefit with BMS/AstraZeneca’s saxagliptin or Takeda’s alogliptin, prompting some commenters to question whether FDA’s blanket approach to CV safety for all antidiabetic agents needs adjustment.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.